Login to Your Account

Biosimilar naming debate ignores confusion with generics

By Mari Serebrov
Washington Editor

Monday, January 6, 2014
The FTC is set to butt into the biosimilar debate next month with a workshop on the potential competitive impacts of proposed naming schemes and state regulations. With its singular focus on competition and the subsequent lowering of drug prices, the FTC plans to ask no questions directly related to safety issues at the Feb. 4 workshop.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription